The global somatostatin analogue drug market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising FDA approvals, advancement in new treatment therapies, and new product launches are some of the key factors contributing to the growth of the hormone therapy replacement therapy market across the globe. According to the American Cancer Society, there are around 5,000 new carcinoid tumors diagnosed in the US each year. According to the National Center for Biotechnology Information, 1 million cases of neuroendocrine tumors (NET) occur every year across the globe which is expected to get increased in the future due to the high adoption of sedentary lifestyles. The NET is found to have low incidence and high prevalence, the high prevalence of NET. The rapid diagnosis of the NET disorder enhances the adoption rate of the drugs for the treatment of the disease, thereby promoting the growth of the somatostatin analogue drug market across the globe.

Get Sample Copy of Somatostatin Analogue Drug Market at: https://www.omrglobal.com/request-sample/somatostatin-analogue-drug-market

Top Key Players - Camurus AB, Chiasma, Inc., Ipsen Group, Boehringer Ingelheim International GmbH, Eli Lilly & Co., F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Tarveda Therapeutics Inc., Teva Pharmaceutical Industries Ltd.

so, on are the prominent players operating in the somatostatin analog drug across the globe. The major players of the somatostatin analogue drug market are making hefty investments in the R&D of new drugs. The continuous efforts of the market players in the development of new drugs are anticipated to make a major contribution to the growth of the somatostatin analogue drug market across the globe.

The recent development in Market

In July 2019, Ipsen UK Ltd. had launched a new pre-filled syringe for Somatuline Autogel (lanreotide). The company has commercialized this syringe to be used on the NHS for the treatment of adult patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs), symptoms associated with neuroendocrine (particularly carcinoid) tumors (NETs), and acromegaly.

For More Information, get A full report of Somatostatin Analogue Drug Market is available at: https://www.omrglobal.com/industry-reports/somatostatin-analogue-drug-market

In June 2018, Novartis International AG had received US FDA approval for Novartis’ Signifor LAR (pasireotide) (a 2nd generation somatostatin analog (SSA)), for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. In addition, Signifor LAR is approved to treat acromegaly patients who have had an inadequate response to the surgery and/or for whom surgery is not an option. The therapy will be available in 20 mg, 40 mg, and 60 mg doses and is administered intramuscularly once every four weeks

Global Somatostatin Analogue Drug Market Segmentation

Type

Octreotide
Lanreotide
Pasireotide
Indication
Neuroendocrine Tumor (NET)
Acromegaly
Others

Global Somatostatin Analogue Drug Market – Segment by Region

North America

United States
Canada

Europe

UK
Germany
Italy
Spain
France
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of the Asia-Pacific
Rest of the World


For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/somatostatin-analogue-drug-market


About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 7803040404